Sawada Hitoshi, Kikukawa Yuhsuke, Ban Susumu, Kakudo Tomoyuki, Yokosawa Hideyoshi
Sugashima Marine Biological Laboratory, Graduate School of Science, Nagoya University, 517-0004 Toba, Japan.
Biochem Biophys Res Commun. 2004 Feb 6;314(2):654-8. doi: 10.1016/j.bbrc.2003.12.143.
In order to examine the possible participation of trypsin-like proteases in the onset and progress of muscular dystrophy, we investigated the expression of the trypsin-like protease in muscular tissues in mdx mice. We found that the mRNAs of several trypsin-like proteases, including hepsin and t-PA, were expressed in the muscular tissues of mdx mice, but at levels not significantly different from normal mice. Since the enzymatic properties of dystrypsin, a muscle trypsin-like protease activated before onset of the disease, are similar to those of thrombin, we investigated the expression pattern of thrombin in mdx mouse muscles. The results showed that prothrombin mRNA is up-regulated in mdx mice at 20-30 days of age but not before the age of 15 days (preclinical). Since protease nexin-1 (PN-1) is known to be a physiological inhibitor of thrombin, we also examined the expression pattern of PN-1. We found that PN-1 transcription and translation is down-regulated in the muscular tissues of mdx mice, before the onset of clinical symptoms. These results suggest that thrombin may be involved in the progression of muscular dystrophy or the regeneration of muscle fibers after the onset of the disease and that the reduced level of PN-1 may enhance the activities stimulate the activities of muscle proteases, including dystrypsin, at a preclinical stage in mdx mice.
为了研究类胰蛋白酶在肌肉萎缩症发病和进展过程中可能的作用,我们调查了类胰蛋白酶在mdx小鼠肌肉组织中的表达情况。我们发现,包括组织蛋白酶H和组织型纤溶酶原激活剂(t-PA)在内的几种类胰蛋白酶的mRNA在mdx小鼠的肌肉组织中均有表达,但表达水平与正常小鼠相比无显著差异。由于在疾病发作前被激活的肌肉类胰蛋白酶——肌萎缩蛋白酶的酶学特性与凝血酶相似,我们研究了凝血酶在mdx小鼠肌肉中的表达模式。结果显示,凝血酶原mRNA在20 - 30日龄的mdx小鼠中上调,但在15日龄(临床前期)之前并未上调。由于蛋白酶抑制因子-1(PN-1)是已知的凝血酶生理性抑制剂,我们也检测了PN-1的表达模式。我们发现,在临床症状出现之前,mdx小鼠肌肉组织中PN-1的转录和翻译均下调。这些结果表明,凝血酶可能参与了肌肉萎缩症的进展或疾病发作后肌纤维的再生,并且PN-1水平的降低可能会在mdx小鼠临床前期增强包括肌萎缩蛋白酶在内的肌肉蛋白酶的活性。